Monova D, Daskalova I, Belovezhdov N
Vutr Boles. 1990;29(6):44-7.
30 patients with hypertension and diabetes mellitus type II were treated with guanfacine (Estulic--"Sandoz" Switzerland) 1 mg tablets in the course of 6 months. The trial began with a placebo period at the end of which the patients were classified into groups: I groups--mild hypertension--14 patients, II group--moderate hypertension--8 patients and III group--severe hypertension - 8 patients. The treatment began in all patients with 0.5 mg Estulic once a day in the evening. According to the effect the dose was increased in one week intervals to 1, 2 and 3 mg daily. A very good effect was achieved in 24 patients (80%), good effect--in 3 patients (10%). There was no effect in 3 patients (10%) with diastolic pressure at the end of the placebo period of 15.3 kP (115 mm Hg). The drug Estulic did not deteriorate the glucose tolerance and in 22 patients (73.3%) a decrease of the blood sugar levels with mean 3.47-1.98 mmol/l was found.
30例高血压合并II型糖尿病患者接受了为期6个月的胍法辛（盐酸胍法辛缓释片——“山德士”，瑞士）1毫克片剂治疗。试验从安慰剂期开始，在此期末将患者分为几组：I组——轻度高血压——14例患者，II组——中度高血压——8例患者，III组——重度高血压——8例患者。所有患者均从每晚一次服用0.5毫克盐酸胍法辛缓释片开始治疗。根据疗效，剂量每隔一周增加至每日1、2和3毫克。24例患者（80%）取得了非常好的疗效，3例患者（10%）疗效良好。3例患者（10%）在安慰剂期末舒张压为15.3千帕（115毫米汞柱），治疗无效。盐酸胍法辛缓释片未使糖耐量恶化，22例患者（73.3%）血糖水平下降，平均下降3.47 - 1.98毫摩尔/升。
